Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;31(2):289-294.
doi: 10.1016/j.annonc.2019.10.022. Epub 2020 Jan 3.

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations

J Mazieres  1 , C Cropet  2 , L Montané  2 , F Barlesi  3 , P J Souquet  4 , X Quantin  5 , C Dubos-Arvis  6 , J Otto  7 , L Favier  8 , V Avrillon  9 , J Cadranel  10 , D Moro-Sibilot  11 , I Monnet  12 , V Westeel  13 , J Le Treut  14 , E Brain  15 , J Trédaniel  16 , M Jaffro  17 , S Collot  17 , G R Ferretti  18 , C Tiffon  19 , C Mahier-Ait Oukhatar  20 , J Y Blay  21
Affiliations
Free article

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations

J Mazieres et al. Ann Oncol. 2020 Feb.
Free article

Abstract

Background: BRAF mutations occurring in 1%-5% of patients with non-small-cell lung cancer (NSCLC) are therapeutic targets for these cancers but the impact of the exact mutation on clinical activity is unclear. The French National Cancer Institute (INCA) launched the AcSé vemurafenib trial to assess the efficacy and safety of vemurafenib in cancers with various BRAF mutations. We herein report the results of the NSCLC cohort.

Patients and methods: Tumour samples were screened for BRAF mutations in INCA-certified molecular genetic centres. Patients with BRAF-mutated tumours progressing after ≥1 line of treatment were proposed vemurafenib 960 mg twice daily. Between October 2014 and July 2018, 118 patients were enrolled in the NSCLC cohort. The primary outcome was the objective response rate (ORR) assessed every 8 weeks (RECIST v1.1). A sequential Bayesian approach was planned with an inefficacy bound of 10% for ORR. If no early stopping occurred, the treatment was of interest if the estimated ORR was ≥30% with a 90% probability. Secondary outcomes were tolerance, response duration, progression-free survival (PFS), and overall survival (OS).

Results: Of the 118 patients enrolled, 101 presented with a BRAFV600 mutation and 17 with BRAFnonV600 mutations; the median follow-up was 23.9 months. In the BRAFnonV600 cohort, no objective response was observed and this cohort was stopped. In the BRAFV600 cohort, 43/96 patients had objective responses. The mean Bayesian estimated success rate was 44.9% [95% confidence intervals (CI) 35.2%-54.8%]. The ORR had a 99.9% probability of being ≥30%. Median response duration was 6.4 months, median PFS was 5.2 months (95% CI 3.8-6.8), and OS was 10 months (95% CI 6.8-15.7). The vemurafenib safety profile was consistent with previous publications.

Conclusion: Routine biomarker screening of NSCLC should include BRAFV600 mutations. Vemurafenib monotherapy is effective for treating patients with BRAFV600-mutated NSCLC but not those with BRAFnonV600 mutations.

Trial registration: ClinicalTrials.gov identifier: NCT02304809.

Keywords: BRAF; basket trial; biomarker; lung cancer; personalised therapy; vemurafenib.

PubMed Disclaimer

Publication types

Associated data